Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LLMs for Healthcare Process Orchestration: Promises and Challenges.

Studies in health technology and informatics·2026
Same author

Challenges of Bringing Augmented Reality into Nursing Medication Preparation.

Studies in health technology and informatics·2026
Same author

Modeling Blood Pressure Monitoring in openEHR: An Implementation Case Study.

Studies in health technology and informatics·2026
Same author

LLMs in Problem-Based Learning: The Grounding Issue.

Studies in health technology and informatics·2026
Same author

Large language models as cognitive shortcuts: a systems-theoretic reframing beyond bullshit.

Frontiers in artificial intelligence·2026
Same author

Metabolic acidosis causes a Fanconi-like syndrome with intracellular trafficking defects and proximal tubule dysfunction.

Science translational medicine·2026
Same journal

A GenAI Pipeline for Violinist Kinematic Data Management.

Studies in health technology and informatics·2026
Same journal

AMAL-For-Qatar: A Comprehensive AI Ecosystem for Fetal Ultrasound Analysis - Project Overview and Achievements.

Studies in health technology and informatics·2026
Same journal

Longitudinal Treatment-Aware Multimodal AI for Dermatology: A Scoping Review.

Studies in health technology and informatics·2026
Same journal

Predicting Postpartum Depression Using Imbalance-Aware Machine Learning.

Studies in health technology and informatics·2026
Same journal

Validation of Deep-Learning Models for Autosegmentation of Brain Metastases.

Studies in health technology and informatics·2026
Same journal

Delay-Dependent Gating in Modular RNNs.

Studies in health technology and informatics·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Modeling Reimbursement-Relevant Drug Data as a Property Graph.

Christian Franke1,2, Murat Sariyar1

  • 1Bern University of Applied Sciences, IODA Institute, Bern, Switzerland.

Studies in Health Technology and Informatics
|July 3, 2026
PubMed
Summary
This summary is machine-generated.

Integrating complex drug data for healthcare reimbursement is challenging. A Neo4j property graph effectively models heterogeneous drug information, simplifying analysis of high-cost medications within the SwissDRG system.

Keywords:
data integrationgraph databasehigh-cost drugsknowledge graph

More Related Videos

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Related Experiment Videos

Last Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Area of Science:

  • Health Informatics
  • Database Management
  • Pharmacoeconomics

Background:

  • Drug-related healthcare data integration is hindered by fragmented, inconsistent public sources.
  • Analyzing high-cost drugs within reimbursement frameworks like SwissDRG requires reconciling diverse data elements.

Purpose of the Study:

  • To evaluate the utility of a Neo4j property graph for integrating and analyzing drug reimbursement data.
  • To assess the suitability of property graph modeling for complex, heterogeneous drug information.

Main Methods:

  • Public data from SwissDRG, EMA, Refdata, Swiss reimbursement sources, and WHO ATC/DDD were preprocessed using R and Python.
  • Data were modeled as a labeled property graph in Neo4j, encompassing over 27,000 nodes and 41,000 relationships.

Main Results:

  • The property graph enabled integrated traversal across drug products, substances, indications, ATC groups, and reimbursement elements.
  • The model facilitated indication-centered exploration and preserved indirect, source-specific links, reducing manual reconciliation efforts.

Conclusions:

  • Property-graph modeling is a robust approach for managing heterogeneous, weakly aligned drug reimbursement data.
  • This method enhances analytical capabilities for complex drug information in healthcare reimbursement contexts.